 Eiger BioPharmaceuticals Inc NASDAQ: EIGR announced an oral poster presentation of Phase 2 study results of Avexitide in congenital hyperinsulinism HI at the American Diabetes Association Scientific Session. HI is an ultra-rare, life-threatening pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50 of children. 